Overview

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
Phase:
Phase 3
Details
Lead Sponsor:
GRADE Study Group
Collaborators:
Becton, Dickinson and Company
Bristol-Myers Squibb
Centers for Disease Control and Prevention
Hoffmann-La Roche
Merck Sharp & Dohme Corp.
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Novo Nordisk A/S
Roche Diagnostics
Sanofi
Treatments:
Dipeptidyl-Peptidase IV Inhibitors
Glimepiride
Insulin
Insulin Glargine
Insulin, Globin Zinc
Liraglutide
Sitagliptin Phosphate